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Guillain-Barré syndrome (GBS) has been described after solid organ and bonemarrow transplantationmostly due to viral infections
and possibly calcineurin inhibitors. Incidence after bone marrow transplant is 0.3–0.7%, though incidence in other transplants is
not well known. We present the first description of tacrolimus associated GBS in lung transplant recipients in the English language
literature. The pathophysiology of tacrolimus-induced polyneuropathy is not known, but some have hypothesized that tacrolimus
induces an inflammatory phenomenon by differential effects on T cell subsets. Diagnosis of association may be challenging and
requires high index of suspicion. The optimal treatment of GBS-associated with tacrolimus after lung transplantation is unknown,
although drug discontinuationmay result in improvement in some patients, while some reports suggest that the use of IVIG and/or
plasmapheresis may be helpful and safe in organ transplant recipients with severe symptoms.
1. Introduction
Guillain-Barré syndrome (GBS) is an autoimmune neurolog-
ical disorder characterized by acute demyelinating changes
of the peripheral nervous system that result in an ascending
paralysis and characterized by severe bilateral symmetric
weakness of the limbs [1].Themajority of cases are associated
with an upper respiratory tract infection, gastrointestinal
illness, or recent immunization, but a wide variety of infec-
tions and exposures have been described in association
with the syndrome [2]. GBS can occur after liver, kidney,
heart, lung, and bone marrow transplantation [3]. Although
viral infections are the most common attributable cause in
organ transplant recipients, calcineurin inhibitors have been
postulated as a potential cause ofGBS.We describe the course
and treatment of two lung transplant recipients diagnosed
with GBS occurring in association with the use of tacrolimus.
2. Case Report 1
A 68-year-old male with history of COPD presented four
months after bilateral lung transplantation complaining
of dizziness, generalized weakness, fatigue, and difficulty
in ambulating. His immediate postoperative course was
uncomplicated and pulmonary function testing was normal
after a three-month follow-up. The patient’s medications
included prednisone (20mg/day), mycophenolate mofetil
(1000mg twice/day), and tacrolimus (5mg twice/day). The
patient denied a history of upper respiratory infection,
diarrhea, recent travel, immunization, or use of new
medications prior to the beginning of his symptoms. Physical
examination showed normal upper extremities motor
strength and symmetric mild reduction of lower extremity
strength (3/5) without sensory deficits. Deep tendon reflexes
were normal. Tacrolimus level was adjusted to therapeutic
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target of 10 ng/mL (range 8–12 ng/mL). The average
measured tacrolimus level during the prior three months
was 10.5 ± 4.1 ng/mL. Microbiology results were negative for
cytomegalovirus (CMV) and Epstein Barr virus (EBV) DNA
by PCR in the serum. An MRI of the head with contrast was
normal. Approximately two weeks later, the patient reported
further decline in motor strength and inability to ambulate.
Physical exam revealed hypoactive deep tendon reflexes
and symmetric bilateral lower extremity weakness (1/5). The
patient underwent a lumbar puncture which revealed protein
of 76mg/dL and glucose of 68mg/dL. Urine, blood, and CSF
cultures were negative for bacteria, fungi, and viruses, while a
repeat serumCMVDNAbyPCRwas negative. AnMRI of the
spine revealed mild degenerative cervical spine disease with-
out evidence of spine compression. Electromyogram (EMG)
and nerve conduction studies showed increased latency and
decreased amplitude of the left ulnar sensory and left sural
sensory and decreased conduction velocity and decreased
amplitude of the left tibial motor and left ulnar motor
consistent with an acute demyelinating polyneuropathy
with axonal changes. At this point, the patient’s neurological
findings were felt to be secondary to GBS associated with
tacrolimus. Tacrolimus was discontinued and the patient was
started on cyclosporine. Approximately ten days later, the
patient continued with inability to ambulate and developed
severe dyspnea. At this point, the patient FEV
1
decreased by
50% from baseline. The patient was admitted to the ICU and
was treated with five sessions of total plasma exchange. Due
to the possible association between calcineurin inhibitor
use and neurotoxicity, cyclosporine was discontinued and
the patient was started on sirolimus. After completion of
plasmapheresis, the patient reported a 50% increase in his
lower extremity motor strength. Repeat neurophysiologic
testing showed improvement in EMG and nerve conduction
studies. Over the next several weeks, the patient continued
to improve and was discharged from the hospital to complete
outpatient rehabilitation. During follow-up, the patient
reported episodes of orthostatic hypotension refractory
to treatment with fludrocortisones, midodrine, and salt
supplementation. These symptoms were attributed to
autonomic dysfunction associated with GBS. The symptoms
ultimately resolved and the patient was able to regain full
physical strength approximately three months later.
3. Case Report 2
A 71-year-old male with a history of idiopathic pulmonary
fibrosis was seen in clinic eight months after undergoing
single lung transplantation with complains of generalized
malaise, fatigue, lower extremity weakness, and difficulty
in ambulating. His immediate postoperative course was
complicated by a fall resulting in a T8 compression frac-
ture not associated with spinal cord injury and requiring
nonoperative medical management. Patient’s medications
during this visit included prednisone (15mg/day), mycophe-
nolate mofetil (1000mg twice/day), and tacrolimus (2.5mg
twice/day). Tacrolimus level was adjusted to therapeutic
target of 10 ng/mL (range 8–12 ng/mL).The averagemeasured
tacrolimus level during the prior six months was 9.4 ±
3.8 ng/mL. Physical examination during this visit showed
evidence of decreased motor strength in lower extremities
(2/5) and decreased deep tendon reflexes. There were no
sensory deficits. An MRI of the spine showed evidence of
prior T8 compression fracture but no spinal cord injury.
Lumbar puncture revealed CSF glucose of 76mg/dL and
protein of 265mg/dL. Blood, urine, and CSF cultures were
negative for bacterial, viral, or fungal organisms, and serum
CMV DNA by PCR was negative. Acetylcholine receptor
antibody levels (binding, blocking, andmodulating) were not
elevated. AnEMGrevealed polyneuropathy and both sensory
and motor axonal demyelination. Nerve conduction studies
revealed that motor and sensory conduction studies of the
left leg and left arm were significant for absent left sural
and ulnar sensory, low amplitude left tibial motor, borderline
prolonged latency, and reduced conduction velocity left ulnar
motor. Again, the patient’s weakness was felt to be consistent
with GBS secondary to tacrolimus. The patient was started
on plasmapheresis and reported subjective improvement in
his lower extremity strength after two sessions of therapy.
Tacrolimus was discontinued and sirolimus (4mg/daily) was
added to the patient’s immunosuppressive regimen. At the
time of his discharge, the patient was able to ambulate with
minimal assistance and was referred to outpatient physical
therapy to continue his rehabilitation.
4. Discussion
We describe two cases of GBS attributed to tacrolimus use
after lung transplantation. GBS is an uncommon disease with
a worldwide incidence of 1 to 2 cases per 100,000/year [4],
whereas the incidence of GBS occurring after solid or bone
marrow transplantation is not known. Studies describing
complications in bone marrow transplant recipients suggest
an incidence of GBS of 0.3–0.7% [5, 6], while a previous
review of the literature that included all cases of GBS in
transplant recipients found only 30 cases of GBS occurring
after solid organ transplantation (13 liver, 6 heart and lung,
and 11 kidney transplant recipients). In the majority of these
reports, male patients are affected more frequently than
females and the onset of symptoms occurred within three
months to one year of the transplant [7].
Frequently described as an autoimmune disorder, GBS
has been thought to be rare among transplant patients,
and immunosuppression has been considered by some as
“protective” for the development of GBS [8]. Nevertheless,
reports of GBS developing in immunocompromised hosts
such as patients with acute leukemia, HIV, and bone marrow
transplant recipients demonstrate thatGBSmay occur despite
profound immunosuppression [9].
Among transplant recipients, GBS has been mostly asso-
ciated with cytomegalovirus infection and recent immuniza-
tion use [7, 10]. Alternatively, the use of tacrolimus has
been postulated by some as a possible and rare cause of
GBS in this population. Bronster et al. described a patient
developing a subacute form of demyelinating sensorimotor
polyneuropathy four months after liver transplantation. The
authors concluded that the neurological findings were caused
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by tacrolimus and the patient improved after drug discon-
tinuation [11]. Similarly, Kaushik et al. described a patient
developingMiller-Fischer variant of GBS in a liver transplant
recipient. In this report, the authors used the Naranjo
probability scale and postulated a probable relation between
the clinical manifestations and tacrolimus therapy [12]. The
pathophysiology of tacrolimus-induced polyneuropathy is
not known, but some have hypothesized that tacrolimus
induces an inflammatory phenomenon by differential effects
on T cell subsets [13].
To our knowledge, our report is the first that suggests
an association between GBS and tacrolimus in lung trans-
plantation. GBS occurring after lung transplantation has
rarely been reported in the literature. Falk et al. described a
lung transplant recipient developing GBS in association with
cyclosporine [14]. Interestingly, our first case presented with
clinical features of autonomic dysfunction similar to those
described by Falk et al. in their report.
The differential diagnosis of GBS after organ trans-
plantation in patients receiving tacrolimus includes periph-
eral sensorimotor polyneuropathy and chronic inflamma-
tory demyelinating polyneuropathy (CIDP). The associa-
tion between tacrolimus and peripheral mononeuropathy
or polyneuropathy is well described in the literature [15].
The pathophysiology of tacrolimus-neurotoxicity is not well
studied, althoughmost cases are described in associationwith
high systemic levels of the drug [16, 17]. Although nerve
conduction studies in patients with tacrolimus polyneu-
ropathy may also show evidence of demyelinating changes,
the symmetric ascending presentation and the absence of a
history of elevated tacrolimus levels favor the diagnosis of
GBS over tacrolimus polyneuropathy in our patients.
CIDP has been rarely reported affecting transplant
patients. Nevertheless, a recent prospective study found an
incidence of 0.6% among 1557 solid organ transplant recip-
ients suggesting a higher prevalence in transplant recipients
compared to the general population [18]. CIDP shares many
features with GBS and therefore establishing the correct
diagnosis may be sometimes difficult. The latter is frequently
described as an acute clinical syndrome, whereas symp-
toms in CIDP tend to progress slowly over eight weeks or
several months. In addition, patients with GBS frequently
have prominent motor involvement with relatively few sen-
sory findings, and autonomic dysfunction is uncommon in
patients with CIDP [19].
The optimal treatment of acute or chronic demyelinating
polyneuropathy associated with tacrolimus in transplant
recipients is unknown. Several reports of liver and renal
transplant patients treated with IVIG and/or plasmapheresis
show that these therapies are successful and result in neu-
rological improvement, although other reports of tacrolimus
induced polyneuropathy also suggest that discontinuation of
the drug without further therapy results in similar improve-
ment [20]. Labate et al. described a heart transplant recipient
with clinical features suggestive of CIDP with improvement
of clinical findings and resolution of demyelinating features
three months after discontinuation of tacrolimus [21]. In
our first case, discontinuation of tacrolimus did not result
in improvement of the symptoms, although due to severity
of the weakness we initiated plasma exchange soon after
tacrolimus discontinuation. While it is possible that both
patients could have improved clinically without further
therapy after drug discontinuation, we elected for plasma
exchange therapy due to the severity of their neurologic
derangements.
We conclude that GBS after organ transplantation is rare.
Nevertheless, recent reports suggest that chronic demyeli-
nating polyneuropathy may be more common in transplant
recipients than in the general population [18]. In addition, it is
likely that the disease is underrecognized and many patients
may be erroneously diagnosed with physical deconditioning
or peripheral polyneuropathy associated with comorbid con-
ditions (i.e., diabetes, etc.). If undiagnosed, these conditions
may lead into severe disability; therefore, we feel that trans-
plant physicians must be aware of the possible association
between tacrolimus and GBS or CIDP.The optimal treatment
of GBS associated with tacrolimus after lung transplantation
is unknown, although drug discontinuation may result in
improvement in some patients, while most reports suggest
that the use of IVIG and/or plasmapheresis may be helpful
and safe in organ transplant recipients with severe symptoms.
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